- $250.84m
- $234.90m
- $4.41m
Brief: Ocugen Clinical Showcase Highlighting Progress In Retinal Gene Therapy Clinical Trials In New York City On Tuesday, November 12, 2024
Ocugen rises after FDA lifts clinical hold on diabetic eye damage therapy
Brief: Ocugen, Inc. Announces Removal Of Clinical Hold On Investigational New Drug Application For Ocu200 Phase 1 Clinical Trial
U.S. STOCKS ON THE MOVE-Chewy, Abercrombie & Fitch, Kohl's
Ocugen rises on completing patient dosing in early-stage gene therapy trial
Ocugen Inc reports results for the quarter ended in June - Earnings Summary
Ocugen Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Ocugen Announces Pricing Of $35 Mln Public Offering Of Common Stock
Brief: Ocugen Announces First Patient Dosed In Phase 3 Trial For OCU400—First Gene Therapy In Phase 3 With A Broad Retinitis Pigmentosa Indication
Ocugen Inc reports results for the quarter ended in March - Earnings Summary
Ocugen Inc expected to post a loss of 6 cents a share - Earnings Preview
Ocugen Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Ocugen Says OCU400 Remains On Track For 2026 BLA And MAA Approval Targets
U.S. STOCKS ON THE MOVE-Perpetua Resources, Huntington Bancshares, FuelCell Energy
U.S. STOCKS ON THE MOVE-JPMorgan, Ameresco, Copper miners
U.S. STOCKS ON THE MOVE-Ocugen, Model N, Fastly
Ocugen rises on FDA nod to eye disorder gene therapy trial
Brief: Ocugen Announces Initiation Of Enrollment In Medium Dose For OCU410—A Modifier Gene Therapy—In Phase 1/2 Armada Study For Geographic Atrophy
Brief: Ocugen Provides Business Update With Certain Financials For The Year Ending 2023